Northern Data AG Opens First Own Data Center in Frankfurt
30.11.2020 10:58:00 EET | Business Wire | Press release
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87) starts operating its first data center at its Frankfurt am Main location. From December 2020, the Frankfurt location will make up part of the Company's Distributed Computing Cluster, based on its mobile high-tech data centers. This will add to the Company's worldwide network of GPU clusters, including in the Netherlands, Scandinavia and Canada. Feasibility studies (Proof of Concept) are planned at the Frankfurt site in cooperation with research and industry.
Stefan Sickenberger, COO of Northern Data, explains: "High-Performance Computing has become an integral part of research and large parts of industry. Parallel processor systems and clusters are needed to process large volumes of data at high speed and with maximum stability. A key driver of success is lower energy consumption and high power efficiency. We are pleased to be working closely with our research partners on this project. We are particularly proud of our cooperation with the High-Performance Computing Architecture group at the Goethe University Frankfurt, which commands a great deal of expertise, especially in the area of Green IT".
Volker Lindenstruth, Professor of High-Performance Computing Architecture at Frankfurt Goethe University and member of the Board of Directors of the Frankfurt Institute for Advanced Studies (FIAS) comments: "We are delighted to be working with Northern Data. This project involves coupling the research supercomputers of Goethe University and the GSI Helmholtz Centre for Heavy Ion Research with Northern Data's own supercomputers, making the best use possible out of our combined capabilities and existing hardware. Peak loads can be intercepted, while particularly large jobs can be started with minimal delay. Example scientific applications include calculations and modelling in particle physics and relativistic astrophysics, environmental and atmospheric physics, as well as applications in life sciences, for example, precise and automated detection of cancer cells in tissue sections.
Aroosh Thillainathan, CEO of Northern Data, adds: "Above all, our concept of 'design-to-cost' is particularly important to this project. We not only manage the customer's data center and hardware but also the software, enabling us to optimize the data center operations to meet the customer's actual needs. In contrast to pure colocation providers, which have no influence on, for example, the load distribution of their customers and their software processing within the data center, we are able to regulate this with our management software. Among other things, we also control the cooling capacity very efficiently in terms of the required computing power, and this enables us to achieve excellent PUE values. Our customers save energy and achieve cost savings as a result. Together with our targeted selection of locations in northern regions, this allows us to offer our customers high-quality HPC solutions tailored to their needs, while remaining extremely cost-efficient at the same time.
About Northern Data:
Northern Data AG develops and operates global infrastructure solutions in the field of High-Performance Computing (HPC). With its customer-specific solutions, the company provides the infrastructure for various HPC applications in areas such as bitcoin mining, artificial intelligence, blockchain, big data analytics, IoT or rendering. The internationally active company is today a leading provider of HPC solutions worldwide. Northern Data offers its HPC solutions both in large, stationary data centers and in mobile high-tech data centers that can be set up at any location worldwide. The company combines self-developed software and hardware with intelligent concepts for a sustainable energy supply. The Northern Data group currently employs about 150 members of staff.
Disclaimer:
This press release does not constitute an offer to sell or a solicitation of an offer to purchase or subscribe for any securities of Northern Data AG, nor does it constitute a securities prospectus of Northern Data AG. The information contained in this press release is not intended to serve as a basis for financial, legal, tax or other business decisions. Investment or other decisions should not be based solely on this press release. As with all business and investment matters, please consult qualified professional advice.
|
Language: |
English |
|
Company: |
Northern Data AG
|
|
Phone: |
+49 69 34 87 52 25 |
|
E-mail: |
|
|
Internet: |
|
|
ISIN: |
DE000A0SMU87 |
|
WKN: |
A0SMU8 |
|
Listed: |
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate Exchange |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201129005436/en/
Contact information
Northern Data AG
Dr. Hans Joachim Dürr
Head of Corporate Communications
e-mail: h.duerr@northerndata.de
Phone: +49 69 348 752 89
Investor Relations:
Sven Pauly
e-mail: ir@northerndata.de
Phone: +49 89 125 09 03 30
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
